| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis
|
Maiorano, B.A.
|
|
|
7 |
5 |
p.
|
article
|
| 2 |
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial
|
Capoluongo, E.D.
|
|
|
7 |
5 |
p.
|
article
|
| 3 |
A phase III randomized, controlled trial of nedaplatin versus cisplatin concurrent chemoradiotherapy in patients with cervical cancer
|
Yang, X.
|
|
|
7 |
5 |
p.
|
article
|
| 4 |
A phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancer
|
Carlsson, G.
|
|
|
7 |
5 |
p.
|
article
|
| 5 |
Assessment of the clinical and cost-effectiveness evidence in the reimbursement decisions of new cancer drugs
|
Chauca Strand, G.
|
|
|
7 |
5 |
p.
|
article
|
| 6 |
Association between recent pregnancy or hormonal contraceptive exposure and outcome of desmoid-type fibromatosis
|
Debaudringhien, M.
|
|
|
7 |
5 |
p.
|
article
|
| 7 |
Association of C-reactive protein with efficacy of avelumab plus axitinib in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101
|
Tomita, Y.
|
|
|
7 |
5 |
p.
|
article
|
| 8 |
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM)
|
Ciardiello, D.
|
|
|
7 |
5 |
p.
|
article
|
| 9 |
Diagnostic work-up and systemic treatment for advanced non-squamous non-small-cell lung cancer in four Southeast Asian countries
|
Soo, R.
|
|
|
7 |
5 |
p.
|
article
|
| 10 |
Editorial Board
|
|
|
|
7 |
5 |
p.
|
article
|
| 11 |
EPIC: an evaluation of the psychological impact of early-phase clinical trials in cancer patients
|
Jittla, P.
|
|
|
7 |
5 |
p.
|
article
|
| 12 |
Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer
|
Wuerstlein, R.
|
|
|
7 |
5 |
p.
|
article
|
| 13 |
Gender representation on editorial boards of leading oncology journals
|
Dai, N.
|
|
|
7 |
5 |
p.
|
article
|
| 14 |
Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment
|
Aamdal, E.
|
|
|
7 |
5 |
p.
|
article
|
| 15 |
How to read a next-generation sequencing report—what oncologists need to know
|
Schmid, S.
|
|
|
7 |
5 |
p.
|
article
|
| 16 |
Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment
|
Su, E.
|
|
|
7 |
5 |
p.
|
article
|
| 17 |
Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials
|
Filis, P.
|
|
|
7 |
5 |
p.
|
article
|
| 18 |
Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study
|
Simonelli, M.
|
|
|
7 |
5 |
p.
|
article
|
| 19 |
Letter re: Neoadjuvant chemoradiotherapy is superior to chemotherapy alone in surgically treated stage III/N2 non-small-cell lung cancer: a retrospective single-center cohort study
|
Zhang, J.
|
|
|
7 |
5 |
p.
|
article
|
| 20 |
Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study
|
Boni, V.
|
|
|
7 |
5 |
p.
|
article
|
| 21 |
Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis ☆
|
Gulia, S.
|
|
|
7 |
5 |
p.
|
article
|
| 22 |
Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A
|
Catenacci, D.V.T.
|
|
|
7 |
5 |
p.
|
article
|
| 23 |
Methylation subgroup and molecular heterogeneity is a hallmark of glioblastoma: implications for biopsy targeting, classification and therapy
|
Gempt, J.
|
|
|
7 |
5 |
p.
|
article
|
| 24 |
MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF wt metastatic colorectal cancer ☆
|
Tabernero, J.
|
|
|
7 |
5 |
p.
|
article
|
| 25 |
Multimodal survival prediction in advanced pancreatic cancer using machine learning
|
Keyl, J.
|
|
|
7 |
5 |
p.
|
article
|
| 26 |
Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors ☆
|
Park, H.
|
|
|
7 |
5 |
p.
|
article
|
| 27 |
Recurrent or primary metastatic cervical cancer: current and future treatments
|
Gennigens, C.
|
|
|
7 |
5 |
p.
|
article
|
| 28 |
Retrospective analysis of the prognostic implications of tumor spread through air spaces in lung adenocarcinoma patients treated with surgery
|
Gutierrez-Sainz, L.
|
|
|
7 |
5 |
p.
|
article
|
| 29 |
Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern
|
Lasagna, A.
|
|
|
7 |
5 |
p.
|
article
|
| 30 |
Table of Contents
|
|
|
|
7 |
5 |
p.
|
article
|
| 31 |
The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression
|
Kim, C.M.
|
|
|
7 |
5 |
p.
|
article
|
| 32 |
The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report
|
Hardenberg, M.C.
|
|
|
7 |
5 |
p.
|
article
|
| 33 |
Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors
|
Le Tourneau, C.
|
|
|
7 |
5 |
p.
|
article
|
Journal description